Molecular Biology Program
The Andrew Koff Lab
My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major focus of the laboratory is directed towards understanding how these gene products are regulated to accomplish these roles.
Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, and Koff A. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 10: 8226-43, 2015
Abbas Manji G, Singer S, Koff A, and Schwartz GK. Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Educ Book. 2015:213-8
Dickson MA, Schwartz GK, Keohan ML, D’Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, and Tap WD. Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.
Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, and Koff A. ATRX is a novel regulator of therapy induced senescence in human cells. Nat. Comms, 8:386, 2017
Kovatcheva M, Klein ME, Tap WD, and Koff A. Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. Mol Cell Oncol 5:e1384882, 2018
Andrew Koff, PhD
- Molecular biologist Andrew Koff is interested in identifying the genes and and molecular mechanisms by which cells make decisions regarding their proliferative capacity after they exit from the cell cycle during therapy induced senescence and during normal development.